Novartis AG (NVS) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Novartis Ag.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:06.015 Good morning and good afternoon and welcome to the Novartis Q1 2025 00:00:06.217 -- 00:00:10.341 results release conference call and live webcast. 00:00:10.341 -- 00:00:15.627 Please note that during the presentation all participants will be in a listen only 00:00:15.627 -- 00:00:18.630 mode and the conference is being recorded. 00:00:18.630 -- 00:00:23.955 After the presentation there will be an opportunity to ask questions 00:00:23.955 -- 00:00:28.482 by pressing star 1 1 at any time during the conference. 00:00:28.482 -- 00:00:34.288 please limit yourself to one question and return to the queue for any follow-ups. 00:00:34.288 -- 00:00:39.513 A recording of the conference call, including the Q&A session, will be available on 00:00:39.513 -- 00:00:44.698 our website shortly after the call ends. With that, I would like to hand over 00:00:44.698 -- 00:00:48.822 to Ms. Sloane Simpson, Head of Investor Relations. 00:00:48.822 -- 00:00:49.963 Please go ahead, madam. 00:00:49.963 -- 00:00:55.328 Thank you, Heidi. Good morning and good afternoon, everyone, and welcome to our Q1 00:00:55.328 -- 00:01:00.671 2025 earnings call. The information presented today contains forward-looking 00:01:00.671 -- 00:01:05.856 statements that have involved known and unknown risks, uncertainties, and other factors. 00:01:05.856 -- 00:01:10.581 These may cause actual results to be materially different from any future results, performance, 00:01:10.581 -- 00:01:14.164 or achievements expressed or implied by such statements. 00:01:14.164 -- 00:01:18.308 For a description of some of these factors, please refer to the company's Form 20-S and 00:01:18.308 -- 00:01:23.373 its most recent quarterly results on Form 6-K that respectively were filed with and 00:01:...